Namdar, M; Kampmann, C; Steffel, J et al.
PQ Interval in Patients With Fabry DiseaseAMERICAN JOURNAL OF CARDIOLOGY. Bd. 105. H. 5. 2010 S. 753-756
Pineda, M; Mengel, E; Wraith, JE et al.
PRELIMINARY DATA FROM AN INTERNATIONAL DISEASE REGISTRY FOR NIEMANN-PICK DISEASE TYPE CJOURNAL OF INHERITED METABOLIC DISEASE. Bd. 33. 2010 S. S146-S146
Zepp, F
Principles of vaccine design-Lessons from natureVACCINE. Bd. 28. 2010 S. C14-C24
Bockius, D; Jung, T; Neuhausen, P et al.
Proposal on an evaluation form for the standardized indication of physiotherapy and occupational therapy and scientific application in neonatology [Abstract]; Neuropediatrics;412010
Herrero, C; Planells, M; Pintos-Morell, G et al.
Renal manifestations in chidren with Fabry disease. Data from FOS - The Fabry Outcome SurveyPEDIATRIC NEPHROLOGY. Bd. 25. H. 3. 2010 S. 578-578
Knuf, M; Vetter, V; Celzo, F et al.
Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix (TM) IPV)HUMAN VACCINES. Bd. 6. H. 7. 2010 S. 554-561
Ramaswami, U; Parini, R; Beck, M
Safety of agalsidase alfa in Fabry disease patients under 7 years oldMOLECULAR GENETICS AND METABOLISM. Bd. 99. H. 2. 2010 S. S32-S32
Kamin, W; Kopp, MV; Erdnuess, F et al.
Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneouslyPEDIATRIC ALLERGY AND IMMUNOLOGY. Bd. 21. H. 1. 2010 S. E160-E165
Knuf, M; Zepp, F; Meyer, CU et al.
Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 monthsEUROPEAN JOURNAL OF PEDIATRICS. Bd. 169. H. 8. 2010 S. 925-933
Kieninger, DM; Kueper, K; Steul, K et al.
Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in GermanyVACCINE. Bd. 28. H. 25. 2010 S. 4192-4203